Phase Ib/II study of Pembrolizumab with Lanreotide depot for advanced, progressive Gastroenteropancreatic neuroendocrine tumors (PLANET)
- 11 February 2025
- journal article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 37 (4) , e13496
Abstract
While performing a study of immune checkpoint blockade with the anti‐PD‐1 antibody pembrolizumab combined with the somatostatin analogue (SSA) lanreotide in patients with low‐ and intermediate‐grade gastroenteropancreatic neuroendocrine tumors (GEP‐NETs), we studied whether there were any immune correlates of response to the anti‐PD‐1 therapy that could guide future attempts to integrate immunotherapy into the treatment of NETs. Patients with grade 1 and 2 GEP‐NETs who had progressed on a prior SSA received lanreotide 90 mg subcutaneously and pembrolizumab 200 mg intravenously every 3 weeks until progression or intolerable toxicity. Objective response rate (ORR) at any time in the study, clinical benefit rate (CBR, defined as stable disease or better), progression‐free survival (PFS), and overall survival (OS) were measured. Changes in T cell subsets in peripheral blood before and during therapy were analyzed by multiparameter mass cytometry (CyTOF). Archived tissue samples were analyzed for PD‐L1 expression and TIL infiltration. Twenty‐two (22) patients (GI/pancreatic 14/8, median Ki67 7% [IQR 4, 10%], median 1.5 prior systemic therapies [range 1–4]) were enrolled. Among the GI‐NETs, there was one partial response, the CBR was 50%, the median PFS was 8.5 months, and the median OS was 32.7 months. No responses were seen in pancreatic NETs, which had 0% CBR, a PFS of 2.7 months, and an OS of 23.9 months. Of the 16 analyzable tumors, 6 had detectable PD‐L1 expression and 15 had detectable TILs. Neither TILs nor PD‐L1 expression correlated with ORR or CBR. However, clinical benefit (SD or better) was associated with peripheral blood on‐treatment effector memory T cell activation and progressive disease was associated with baseline peripheral blood regulatory T cell (Treg) activation. We conclude that immune checkpoint blockade had low activity in unselected patients with grade 1 and 2 GEP‐NETs. Further study of strategies to reduce Treg activation or enhance effector memory activation during immunotherapy is warranted.Keywords
Funding Information
- Ipsen Biopharmaceuticals
This publication has 43 references indexed in Scilit:
- Update in the management of gastroenteropancreatic neuroendocrine tumorsCancer, 2024
- Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trialEuropean Journal of Cancer, 2024
- Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trialsEuropean Journal of Cancer, 2022
- Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine TumorsJAMA Oncology, 2022
- LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)Annals of Oncology, 2021
- Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 studyCancer, 2020
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017
- ggplot22016
- FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry dataCytometry Part A, 2015
- Normalization of mass cytometry data with bead standardsCytometry Part A, 2013